BioSpace News Archive

Entera Bio Ltd. (NASDAQ: ENTX), a leader in the development of orally delivered large molecule therapeutics, announced it will report business and financial results for the quarter ended June 30, 2021, on August 16, 2021, at 06:30am ET.

Biophytis SA announces that it has performed the obligations imposed on it by the judgment of the Commercial Court of Paris of March 16, 2021 and the judgment of July 16, 2021 of the Enforcement Judge of the Judicial Court of Paris in the case opposing Biophytis to Negma Group Ltd in relation to the ORNANEBSA agreement entered into on August 21, 2019.

As COVID-19 activity continues in Canada, we are continuing to track key epidemiological indicators to monitor trends, quickly detect, and understand emerging issues of concern, including the impact of circulating virus variants.

BioAtla, Inc. (Nasdaq: BCAB), a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody therapeutics, today announced financial results for the second quarter of 2021 and provided an update on its business.

Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced the initiation of a rolling submission to Health Canada for molnupiravir, an investigational twice daily oral antiviral agent currently in trials as a potential treatment for COVID-19.

Cybin Inc. (NEO:CYBN) (NYSE AMERICAN:CYBN) (“Cybin” or the “Company”), a biotechnology company focused on progressing psychedelic therapeutics, announces the unaudited financial results for the three-month period ended June 30, 2021.

Merck (NYSE: MRK), today announced that the U.S. Food and Drug Administration (FDA) has approved WELIREG, an oral hypoxia-inducible factor-2 alpha (HIF-2α) inhibitor, for the treatment of adult patients with von Hippel-Lindau (VHL) disease who require therapy for associated renal cell carcinoma (RCC), central nervous system (CNS) hemangioblastomas, or pancreatic neuroendocrine tumors (pNET), not requiring immediate surgery.

A3P Biomedical AB today announced that the publication of the STHLM3 MRI trial including 12,750 men has been fast tracked and is now published in the renowned peer-reviewed scientific publication The Lancet Oncology1.

Transparency Market Research states that the competition in the global veterinary ultrasound scanners market is likely to intensify in the coming few years.

According to the report, the global hyperthermia cancer treatment market was valued at ~US$ 155 Mn in 2019 and is projected to expand at a CAGR of ~6% from 2020 to 2030.